Skip to main content

Table 2 Clinical characteristics of the 34 studies included in the meta-analysis

From: Risk of second breast cancer in female Hodgkin’s lymphoma survivors: a meta-analysis

Author & Year

Country

Year

Design

Source of data

STROBE criteria (met/applicable)

RT only No. (%)

CTX only No. (%)

RT-CTX No. (%)

Comments

Coleman 1987 [23]

UK

1961-1980

PBCS.

Cancer registry

25/32

(35–36)

(20–28)

(27–34)

Therapy data for M + F HL patients. Number NR.

Hancock 1993 [24]

USA

1961–1989

Single institution cohort study

Computerized database and patient records

24/31

383 (43)

30 (3)

341 (39)

Therapy data for M + F HL patients. 15% did not receive any treatment.

Wolden 1998 [30]

USA

1960-1995

Single institution cohort study (HL Dx. ≤21y)

Computerized database and patient records

22/31

144 (47)

9 (3)

154 (50)

Therapy data for female patients

Wolden 2000 [37]

USA

1960-1997

Single institution retrospective review

Computerized database and patient records

24/32

37 (57)

1 (2)

27 (41)

Therapy data for SBC patients. 27 patients received alkylating CTX.

O'Brien 2010 [58]

USA

1970-1990

Single institution study of children

Retrospective chart review and patient questionnaires

23/31

0 (0)

0 (0)

35 (100)

Therapy data for M + F pediatric HL patients. All received low-dose RT and alkylating CTX.

van Leeuwen 1994 [25]

Netherlands

1966-1986

2 institutions cohort study

Institutional registries and patient records

22/30

552 (29)

178 (9)

1209 (62)

Therapy data for M + F HL patients. All SBC received RT.

De Bruin 2009 [55]

Netherlands

1965-1995

6 institutions cohort study (5y survivors)

Medical records, and physician questionnaires

25/32

357 (31.8)

80 (7.1)

685 (61.1)

Therapy data for all HL female patients

Mauch 1996 [26]

USA

1969-1988

5 institutions cohort study

Institutional records

25/31

489 (62)

0 (0)

305 (38)

Therapy data for M + F HL patients

Ng 2002 [41]

USA

1969–1997

4 institutions cohort study

Institutional records

26/32

665 (69)

0 (0)

296 (31)

Therapy data for M + F HL patients

Sankila 1996 [27]

Nordic countries

1940-1987

5 Nordic PBCS (HL Dx. ≤20y)

National cancer registries

21/31

NR

NR

NR

All SBC patients received RT

Metayer 2000 [36]

USA and Europe

1935–1994

16 PBCS (HL Dx. ≤21y, 1-year survivors)

National cancer registries

22/32

NR

NR

NR

 

Hodgson 2007 [48]

USA and Europe

1970-2001

13 PBCS (5-year survivors)

National cancer registries

22/32

6461 (34) 145 (74)

4398 (23) 26 (13)

2847 (15) 36 (18)

First raw: therapy data for M + F HL patients. (27% with unknown treatment). Second raw:therapy data for SBC patients (28% with unknown treatment)

Dores 2010 [57]

USA

1973-2000

9 PBCS (5-year survivors, Dx. ≤35y)

9 cancer registry areas of SEER

22/32

NR

NR

NR

All patients had RT

Aisenberg 1997 [28]

USA

1964-1984

Single institution cohort study

Review of patient records

21/31

10 (71)

0 (0)

4 (29)

Therapy data for SBC patients (4 patients had alkylating CTX)

Alm El-Din 2009 [54]

USA

1964-2001

Single institution cohort study

Review of patient records

21/31

130 (52) 24 (67)

0 (0) 0 (0)

118 (48) 12 (33)

First raw: therapy data for all patients (26% had alkylating CTX) Second raw: therapy data for SBC (22% had alkylating CTX)

Hudson 1998 [29]

USA

1968-1990

Single institution

Review of patient records

21/30

116 (30)

15 (4)

256 (66)

Therapy data of M + F HL patients

Gervais-Fagnou 1999 [31]

Canada

1965-1990

Single institution cohort study (HL Dx. at ≤30y)

Review of patient records

22/30

225 (55)

0 (0)

186 (45)

Therapy data of M + F HL patients

Munker 1999 [32]

Germany

1974-1994

6 institutions cohort study

Munich tumor registry, patient records, and patient & family contact

24/31

484 (43.1)

169 (15.1)

464 (41.4)

Therapy data of M + F HL patients (8/9 SBC patients received RT)

Green 2000 [34]

USA

1960-1989

Single institution cohort study (HL ≤20y at Dx.)

Patient records and mail contact

24/30

1 (25)

0 (0)

3 (75)

Therapy data for SBC patients

Swerdlow 2000 [36]

United Kingdom

1963-1993

BNLI (cohort study)

BNLI + 2 cancer databases

24/31

1449 (27)

1693 (31)

2327 (42)

Therapy data of M + F HL patients (all SBC had RT)

Swerdlow 2011 [62]

United Kingdom

1963-2001

BNLI (cohort study)

BNLI database (70 institutions)

25/31

0 (0)

2366 (41)

3432 (59)

Therapy data of M + F HL patients (SBC: 14% CTX only, 86% CTX + RT)

Cellai 2001 [38]

Italy

1960-1991

Single institution cohort study

Institutional patient records

22/30

546 (36)

325 (21)

653 (43)

Therapy data of M + F HL patients (SBC patients: 6% RT, 94% RT + CTX)

Neglia 2001 [39]

USA and Canada

1970-1986

25 institutions (CCSS) cohort study (≤21y at HL Dx., 5-y survivors)

Institutional patient records

26/32

NR

NR

NR

Therapy data were reported for all children malignancies combined

Kenney 2004 [45]

USA and Canada

1970-1986

Same as Neglia et al. [40]

Institutional patient records

26/32

NR

NR

NR

Therapy data were reported for all children malignancies combined

Castellino 2011 [59]

USA and Canada

1970-1986

Same as Neglia et al. [40] and Kenny et al. [46]

Institutional patient records

26/32

263 (33)

46 (6)

472 (60)

Therapy data for all HL female patients

Foss Abrahamsen 2002 [40]

Norway

1968-1985

Single institution cohort study (HD ≥ 1y survivors)

National cancer registry

21/30

447 (44)

202 (20)

363 (36)

Therapy data of M + F HL patients

Bhatia 2003 [42]

USA and Europe

1955-1986

15 institutions cohort study

Institutional patient records

26/33

314 (23) 14 (47)

106 (8) 0 (0)

960 (69) 15 (53)

First raw: therapy data of M + F HL patients Second raw: therapy data of SBC patients

Wahner-Roedler 2003 [44]

USA

1950-1993

Single institution cohort study

Institutional patient records

23/31

322 (50) 23 (77)

0 (0) 0 (0)

327 (50) 7 (23)

First raw: therapy data of M + F HL patients Second raw: therapy data of SBC patients

Behringer 2004 [60]

Germany

1981-1989

Multi-Institutional cohort study

German HL database

23/31

675 (12.9)

618 (11.8)

3947 (75.3)

Therapy data of M + F HL patients

Guibout 2005 [46]

UK and France

1954-1985

8 institutions cohort study

Institutional patient records

28/32

28 (23)

9 (7)

86 (70)

Therapy data of M + F HL patients

Taylor 2007 [51]

UK

1940-1991

PBCS

National Registry of Childhood Tumors

22/31

121 (37) 7 (44)

63 (20) 0 (0)

138 (43) 9 (56)

First raw: therapy data of female HL patients Second raw: therapy data of SBC patients

Basu 2008 [52] Constine 2008 [53]

USA

1960-1990

5 institutions cohort study (<19y at HL Dx.)

Institutional patient records

22/31

174 (44) 18 (62)

37 (9) 3 (10)

187 (47) 8 (28)

First raw: therapy data of M + F HL patients Second raw: therapy data of SBC patients

Howell 2009 [56]

UK

1965-2008

Cohort from a registry and single institution

Institutional patient records and a registry data

27/31

6 (26)

0 (0)

17 (74)

Therapy data of SBC patients

Inskip 2007 [61]

USA

1973-2002

PBCS (< 18y at Dx)

SEER database

29/31

NR

NR

NR

 
  1. *Absolute excess rate of SBC incidence cases per 10,000 person-years of follow-up.
  2. CI confidence interval, Cum. Cumulative, DCIS ductal carcinoma in-situ, HL Hodgkin’s lymphoma, MF males and females, NR not reported or data could not be calculated, O/E observed/expected, RR relative risk, SBC second breast cancer (unless indicated, all are invasive breast cancer), y year. (Studies shaded together represent overlapping data).